source
- Axiom's stem cell therapy shows zero mortality in phase-1 trial for newborn brain injuriesAxiom Biosciences reported that its mesenchymal stem cell (MSC) therapy achieved a 0% mortality rate over two years in a phase‑1 study of newborns with severe brain injuries. The nine‑patient trial…
- New acting head Karim Mikhail seeks to steady FDA’s biologics center after turbulent leadershipKarim Mikhail, the acting director of the FDA’s Center for Biologics Evaluation and Research, told staff in a town‑hall meeting that he understands the pressures they face and wants to work alongsi…